Literature DB >> 10221816

Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma.

I O Ng1, J M Lee, G Srivastava, M Ng.   

Abstract

Insulin-like growth factor II (IGF-II) is a mitogenic polypeptide closely related to insulin. Its gene has complex regulation of transcription, resulting in multiple mRNA initiated by different promoters. To study its role in hepatocarcinogenesis, we examined the expression of IGF-II mRNA in hepatocellular carcinomas (HCC) and correlated it with the pathological features of the tumours. Using northern blot analysis, transcription of the normal adult promoter was repressed in all but two of the 30 HCC. Instead, there was re-expression of two foetal transcripts (6 and 5 kb) in 12 tumours. In contrast, most (93.3%) of the non-tumorous livers showed expression of adult transcript only, and there were three livers demonstrating expression of foetal transcripts in addition to the adult one. There was a significant association of IGF-II expression with direct tumour invasion into the adjacent liver parenchyma but foetal expression did not influence other parameters directly related to tumour invasiveness, including venous permeation, formation of tumour microsatellites and positive resection margin. Besides, IGF-II expression was significantly more frequently seen in tumours from older patients. To conclude, repression of normal adult promoter and re-expression of foetal promoters of IGF-II are common events in HCC. The observation that foetal IGF-II expression was significantly more frequent in older patients suggests that spontaneous foetal expression of IGF-II late in life may promote the growth of tumours which have already arisen through other mechanisms, but foetal re-expression itself is not enough to contribute to tumour progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10221816     DOI: 10.1111/j.1440-1746.1998.tb00630.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Authors:  Zhi-Zhen Dong; Deng-Fu Yao; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Dao-Rong Jiang; Jian-Hua Zhu; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

2.  Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.

Authors:  Yabing Huang; Ling Huang; Jiling Zhu; Yin Wu; Jinzhi Shi; Kai Dai
Journal:  Clin Exp Immunol       Date:  2022-05-13       Impact factor: 5.732

Review 3.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

4.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553

Review 5.  Targeting insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Jennifer Wu; Andrew X Zhu
Journal:  J Hematol Oncol       Date:  2011-07-05       Impact factor: 17.388

6.  Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers.

Authors:  Qi Zhou; Ying-Qing Mao; Wei-Dong Jiang; Yun-Ru Chen; Ren-Yu Huang; Xiang-Bing Zhou; Ya-Feng Wang; Zhi Shi; Zhong-Sheng Wang; Ruo-Pan Huang
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

7.  [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].

Authors:  M A Kern; K Breuhahn; M Schuchmann; P Schirmacher
Journal:  Pathologe       Date:  2007-07       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.